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Abstract
Understanding why some people establish and maintain effective control of HIV-1 and others do not
is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association
strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals
in viral load during the asymptomatic set-point period of infection. One of these is found within an
endogenous retroviral element and is associated with major histocompatibility allele human leukocyte
antigen (HLA)–B*5701, whereas a second is located near the HLA-C gene. An additional analysis
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of the time to HIV disease progression implicated two genes, one of which encodes an RNA
polymerase I subunit. These findings emphasize the importance of studying human genetic variation
as a guide to combating infectious agents.
Humans show remarkable variation in vulnerability to infection by HIV-1 and especially in
the clinical outcome after infection. One striking and largely unexplained difference is the level
of circulating virus in the plasma during the nonsymptomatic phase preceding the progression
to AIDS. This is known as the viral set point and can vary among individuals by as much as 4
to 5 logs (1–6). We aimed to identify human genetic differences that influence this variation.
To define a homogeneous phenotype for genetic analyses, a consortium of nine cohorts was
formed [termed Euro-CHAVI (Center for HIV/AIDS Vaccine Immunology) (7)], and a total
of 30,000 patients were screened to identify those most appropriate for analysis. All
longitudinal viral-load (VL) data were assessed through a computerized algorithm to eliminate
VL not reflecting the steady state and were individually inspected by an experienced infectious-
disease clinician (Fellay) to exclude suspicious VL data and patients that do not show a clear
set point, leaving 486 patients with a consistent and accurately measured phenotype (7). For
patients with at least four CD4 cell-count results, we defined a progression phenotype as the
time to treatment initiation or to the predicted or observed drop of the CD4 cell count below
350 (7,8).
All samples were genotyped with the use of Illumina's HumanHap550 BeadChip with 555,352
single-nucleotide polymorphisms (SNPs). A series of quality-control steps resulted in the
elimination of 20,251 polymorphisms (7). We applied methods to identify deletions and
targeted copy-number variations and to assess whether they influenced the phenotype (7). Our
core association analyses focused on single-marker genotype-trend tests of the quality control–
passed SNPs, using linear regression (7). To control for the possibility of spurious associations
resulting from population stratification, we used a modified EIGENSTRAT method (7,9). We
assessed significance with a Bonferroni correction (P cutoff = 9.3 × 10−8). Analyses
incorporating human leukocyte antigen (HLA) typing were carried out on a subgroup of 187
patients with available four-digit HLA class I allelic determination.
These analyses identified two independently acting groups of polymorphisms, associated with
HLA loci B and C, that are estimated to explain 9.6 and 6.5% of the total variation in HIV-1
set point, respectively, and can thus be considered as major genetic determinants of viral set
point. A third set located >1 Mb away in the major histocompatibility complex upstream of a
gene that encodes an RNA polymerase I subunit explains 5.8% of the total variation in disease
progression. Together, the three polymorphisms explain 14.1% of the variation in HIV-1 set
point.
One polymorphism located in the HLA complex P5 (HCP5) gene explains 9.6% of the total
variation in set point, despite a minor-allele frequency of 0.05 (Single Nucleotide
Polymorphism database number rs2395029, P = 9.36 × 10−12). A single copy of the controlling
allele was found to result in a reduction in VL of >1 log (Fig. 1); at P = 9.36 × 10−12, this
genome-wide association is significant.
The HCP5 gene is located 100 kb centromeric from HLA-B on chromosome 6 (Fig. 2), and the
associated variant is known to be in high linkage disequilibrium (LD) with the HLA allele
B*5701 (10) (r2 = 1 in our data set). This allele itself has the strongest-described protective
impact on HIV-1 disease progression (11) and has been associated with low VL (12).
Given the strong functional data supporting a role for HLA-B*5701 in restricting HIV-1, our
first hypothesis is that the association observed here is due to the effect of HLA-B*5701,
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reflected in its tagging a SNP within HCP5 (10). We emphasize, however, that genetics allows
no resolution of whether this effect is exclusively due to B*5701 or if HCP5 variation also
contributes to the control. In fact, as a human endogenous retroviral element (HERV) with
sequence homology to retroviral pol genes (13) and confirmed expression in lymphocytes
(14), HCP5 is itself a good candidate to interact with HIV-1, possibly through an antisense
mechanism (14). Moreover, HCP5 is predicted to encode two proteins, and the associated
polymorphism results in an amino acid substitution in one of these proteins.
A model in which HCP5 and HLA-B*5701 have a combined haplotypic effect on the HIV-1
set point is consistent with the observation that suppression of viremia can be maintained in
B*5701 patients with undetectable VL, even after HIV-1 undergoes mutations that allow
escape from cytotoxic T lymphocyte (CTL)–mediated restriction (15). However, this
observation has also been explained by a decrease in viral fitness associated with the escape
variants (16). In addition, B*5701 patients present less frequently with symptoms during acute
HIV-1 infection (12), suggesting control before the time of a maximal CTL response (17).
The second most significant polymorphism we identified, rs9264942, is located in the 5′ region
of the HLA-C gene, 35 kb away from transcription initiation (Fig. 2) and 156 kb telomeric of
the HCP5 gene. This SNP explains 6.5% of the variation in set point (Fig. 1) and shows a
genome-wide significant association (P = 3.77 × 10−9). Despite minor LD between the
HCP5 and HLA-C SNPs (r2 = 0.05, D′ = 0.84), nested regression models clearly demonstrate
an independent effect of each of these variants. In a model including the HCP5 variant, the
addition of the HLA-C variant results in a highly significant increase in explanatory power, as
does the addition of the HCP5 variant to a model already including the HLA-C variant
[supporting online material (SOM) text].
This SNP also associates strongly with differences in HLA-C expression levels, both in the
Sanger Institute Genevar expression database (18) (table S1) and in a replication group of 48
healthy volunteers established for this study (SOM text). The protective allele leads to a lower
VL and is associated with higher expression of the HLA-C gene. This strong and independent
association with HLA-C expression levels suggests that genetic control of expression levels of
a classical HLA gene influences viral control. Other HLA-C 5′ variants also associate with
HLA-C expression but do not contribute independently to viral control (SOM text).
Although these data make a strong case for a causal role for HLA-C expression levels, extensive
LD throughout the MHC region makes it necessary to directly test for alternative causal
variants. Specifically, we used nested regression models to assess whether the observed
association could be determined by described functional HLA class I alleles. In fact, the HLA-
C expression SNP shows association with certain alleles or group of alleles (Tables 1 and 2).
In each case, however, although the HLA-C expression variant can explain the effect of these
alleles on the HIV-1 set point, the reverse is not true. When a linear regression model includes
known HLA alleles, the addition of rs9264942 results in a significant increase in the explained
variation. On the other hand, none of the HLA alleles considered, with the exception of HCP5/
B*5701, adds significantly to a model that already incorporates the HLA-C variant (Tables 1
and 2).
No other single marker reached genome significance, and none of the identified copy-number
variations (7) showed any association with the HIV-1 set point. An analysis comparing the
observed set of P values to that expected under the null hypotheses shows no overall inflation
of P values (indicating little contribution from population stratification) but does show an
excess of low P values, beginning with the 355th most associated SNP (fig. S1). This indicates
that additional real effects are likely to be present among the most associated polymorphisms
in this study (complete list available in table S2). Potentially interesting candidates with a lesser
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association with the set point (listed in tables S3 to S5) were chosen on the basis of their ranking
in the study or their link with HIV-1 biology.
We next identified polymorphisms that associate with progression rather than VL: The
strongest association included a set of seven polymorphisms located in and near the ring finger
protein 39 (RNF39) and zinc ribbon domain–containing 1 (ZNRD1) genes, respectively
(rs9261174, rs3869068, rs2074480, rs7758512, rs9261129, rs2301753, and rs2074479). This
group of polymorphisms explains 5.8% of the variation in progression, with a relative hazard
of 0.64 (fig. S2), and approaches genome-wide significance (P = 3.89 × 10−7). It also associates
with VL at the set point (P = 7.11 × 10−3). These variants are >1 Mb telomeric from the previous
candidates (fig. S3), and their effect on both progression and set point is independent of
HCP5- and HLA-C–related polymorphisms and HLA alleles or groups of alleles previously
implicated in HIV-1 control (SOM text and table S6).
Using the Genevar database and our group of 48 healthy volunteers, we observed that
ZNRD1 expression is significantly associated with the identified SNPs (SOM text and table
S1). Two of them (rs3869068 and rs9261174) are located in a putative regulatory 5′ region, 25
and 32 kb away from the gene, respectively. Because ZNRD1 encodes an RNA polymerase I
subunit, if this gene is responsible for the restriction of HIV-1, the mechanism could involve
interference with the processing of HIV-1 transcripts by the HIV-1 regulatory protein Rev.
Rev is known to be localized in the nucleolus (where RNA polymerase I transcribes ribosomal
RNA), and the blockade of RNA polymerase I has been shown to influence the distribution of
REV, causing a shift from the nucleolus to the cytoplasm (19,20). Efficiency in provirus
transcription is highly variable among individuals; in one study, differences in transcription
efficiency accounted for 64 to 83% of the total variance in virus production that was attributable
to post-entry cellular factors (21).
The second gene, RNF39, is poorly characterized but cannot be ruled out as a candidate because
two of the associated polymorphisms are located in its coding region and result in amino acid
changes (rs2301753 and rs2074479). No other genome-wide significant association was
observed in the analysis of the progression phenotype (SOM text).
We established an independent replication cohort of 140 Caucasian patients, drawn from the
same participating cohorts. For this follow-up study, we relaxed the interval from a documented
negative test to a positive test (for infection) from 2 years to 4 years to identify additional
qualifying study participants. We genotyped representative polymorphisms for the associations
reported above (HCP5, rs2395029; HLA-C, rs9264942; and ZNRD1, rs9261174). Each
association was replicated with effects all in the same direction: HCP5, P = 1.4 × 10−2; HLA-
C, P = 2.8 × 10−3; and ZNRD1, P = 4.8 × 10−2.
We have securely identified at least two mechanisms not previously known to restrict HIV-1:
HLA-C, which has been suspected but never confirmed to contribute to HIV-1 control, and an
RNA polymerase subunit that substantially changes the time course of HIV progression (fig.
S1). We also suggest the possibility that a HERV-derived gene may contribute to the viral
control attributed to the HLA-B*5701 allele. Our findings confirm and emphasize the central
role of the MHC region in HIV-1 restriction, estimate its contribution against all genome
influences, and open up new perspectives in the understanding of its mode of action: It is
necessary to expand HLA analysis to include high-density genotyping. It is also noteworthy
that this genome-wide study of host determinants has three clear discoveries, implying that
determinants of host response may often include gene variants with major effects. This suggests
a degree of urgency in carrying out similar studies for other infectious diseases.
Our results suggest two possible directions for therapeutic intervention. First, if HCP5 and
ZNRD1 contribute to the control associated with HLA-B*5701, they could lead to therapeutic
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applications. On the other hand, the implication of HLA-C in HIV-1 control could present
important opportunities, given that the HIV-1 accessory protein Nef selectively down-regulates
the expression of HLA-A and -B but not that of HLA-C on the surface of infected cells (22).
Originally, this strategy was considered advantageous for the virus because HLA-A and -B
present foreign (notably viral) epitopes to CD8 T cells, resulting in cell destruction, whereas
HLA-C binds self-peptides and interacts with natural killer (NK) cells to avoid NK attack.
However, HLA-C also has the ability to present viral peptides to cytotoxic CD8+ T cells and
consequently to restrict HIV-1 (23,24). Our observations suggest that HLA-C–mediated
restriction may be an important element of viral control in specific genetic backgrounds, and
that the apparent immunity of HLA-C to Nef down-regulation could present an opportunity for
vaccine strategies targeting HLA-C–mediated responses.
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Fig 1.
HIV-1 VL at the set point is highly correlated with (A) the HCP5 rs2395029 genotype, where
T is the major allele and G is the minor allele, and with (B) the HLA-C 5′ region rs9264942
genotype, where T is the major allele and C is the minor allele. Mean and SEM (error bars) are
represented for the respective genotypes.
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Fig 2.
Partial map of the HLA class I region (chromosome 6 p21.3). The P values [−log(P)] of all
genotyped SNPs annotated with the gene structure are indicated. The two independent SNPs
that show genome-wide significant association with HIV-1 VL at the set point are marked in
red. The graph was drawn with WGAViewer software (www.genome.duke.edu/centers/pg2/
index_html/downloads/AnnotationSoftware).
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Table 2
In contrast to Table 1, only HLA-B*5701 has an independent impact after taking into account the effect of
rs9264942. The independence of HLA-C is also clearly seen in the mean values of the HIV-1 set point for each
rs9264942 genotype: The minor allele C is associated with a decrease in VL, independent of all considered alleles
and groups of alleles. Numbers refer to a subgroup of 187 patients with available four-digit HLA class I allelic
results.
rs9264942 genotype Number of patients Mean SD
All patients
TT 67 4.37 0.85
TC 87 3.84 1.19
CC 33 3.24 1.28
Patients without HLA-B*27
TT 66 4.39 0.83
TC 78 3.86 1.21
CC 25 3.13 1.23
Patients without HLA-B*5701
TT 67 4.37 0.85
TC 76 3.97 1.08
CC 27 3.43 1.25
Patients without HLA-B*35Px
TT 56 4.32 0.88
TC 84 3.86 1.17
CC 32 3.23 1.30
Patients without HLA-B*08
TT 50 4.26 0.87
TC 81 3.83 1.22
CC 33 3.24 1.28
Patients without HLA-B*51
TT 56 4.38 0.85
TC 73 3.77 1.17
CC 28 3.21 1.38
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